Most of the brokerages are bullish on Sun Pharma
as the company's July-September quarter (Q2FY21) result addressed most of the key concerns around its operating performance. JM Financial Institutional Equities sees multiple drivers of a sustained earnings momentum including Sun's specialty portfolio now reverting to its normalized growth trajectory, uptick in prescriptions across Taro's key products in the US, and further consolidation of Sun's leadership position in the domestic market.
Laurus Labs, on the other hand, rallied 5 per cent to Rs 333.95 on the BSE in the intra-day deals. The stock was trading close its record high price of Rs 345 touched on October 30, 2020. In the past 10 trading days, it has surged 25 per cent as compared to a 3-per cent rise in the S&P BSE Sensex.
On November 25, Laurus Labs
said it has signed a definitive agreement to acquire 72.55 per cent stake in Richcore Lifesciences Pvt Ltd (Richcore) from Eight Roads Ventures and VenturEast for a value of Rs. 246.7 crore. This acquisition marks Laurus Labs' entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India.
"The acquisition is a step towards building a vertically integrated biotech segment and adds a new lever to growth. It particularly provides capabilities in high growth areas of Recombinant (Rh) Proteins, Enzymes and Biological Contract Development and Manufacturing Organization (CDMO)," Motilal Oswal Financial Services said in post event update. The brokerage firm maintains 'buy' rating on Laurus Labs
with target price of Rs 410 per share.
Among the other individual stocks, Indoco Remedies, Vimta Labs, Sun Pharma
Advanced Research Company, Lupin, Neuland Laboratories, Strides Pharma Science, Glenmark Pharmaceuticals and Cadila Healthcare were up in the range of 2 per cent to 5 per cent on the BSE.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.